Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 79

1.

HIF2α-Targeted RNAi Therapeutic Inhibits Clear Cell Renal Cell Carcinoma.

Wong SC, Cheng W, Hamilton H, Nicholas AL, Wakefield DH, Almeida A, Blokhin AV, Carlson J, Neal ZC, Subbotin V, Zhang G, Hegge J, Bertin S, Trubetskoy VS, Rozema DB, Lewis DL, Kanner SB.

Mol Cancer Ther. 2018 Jan;17(1):140-149. doi: 10.1158/1535-7163.MCT-17-0471. Epub 2017 Oct 27.

2.

RNAi-based treatment of chronically infected patients and chimpanzees reveals that integrated hepatitis B virus DNA is a source of HBsAg.

Wooddell CI, Yuen MF, Chan HL, Gish RG, Locarnini SA, Chavez D, Ferrari C, Given BD, Hamilton J, Kanner SB, Lai CL, Lau JYN, Schluep T, Xu Z, Lanford RE, Lewis DL.

Sci Transl Med. 2017 Sep 27;9(409). pii: eaan0241. doi: 10.1126/scitranslmed.aan0241.

3.

Phosphorylation-specific status of RNAi triggers in pharmacokinetic and biodistribution analyses.

Trubetskoy VS, Griffin JB, Nicholas AL, Nord EM, Xu Z, Peterson RM, Wooddell CI, Rozema DB, Wakefield DH, Lewis DL, Kanner SB.

Nucleic Acids Res. 2017 Feb 17;45(3):1469-1478. doi: 10.1093/nar/gkw828.

4.

Synthesis and Biological Evaluation of Pyrazolo[1,5-a]pyrimidine Compounds as Potent and Selective Pim-1 Inhibitors.

Xu Y, Brenning BG, Kultgen SG, Foulks JM, Clifford A, Lai S, Chan A, Merx S, McCullar MV, Kanner SB, Ho KK.

ACS Med Chem Lett. 2014 Oct 22;6(1):63-7. doi: 10.1021/ml500300c. eCollection 2015 Jan 8.

5.

A small-molecule inhibitor of PIM kinases as a potential treatment for urothelial carcinomas.

Foulks JM, Carpenter KJ, Luo B, Xu Y, Senina A, Nix R, Chan A, Clifford A, Wilkes M, Vollmer D, Brenning B, Merx S, Lai S, McCullar MV, Ho KK, Albertson DJ, Call LT, Bearss JJ, Tripp S, Liu T, Stephens BJ, Mollard A, Warner SL, Bearss DJ, Kanner SB.

Neoplasia. 2014 May;16(5):403-12. doi: 10.1016/j.neo.2014.05.004. Epub 2014 Jun 18.

6.

Discovery of 3-(trifluoromethyl)-1H-pyrazole-5-carboxamide activators of the M2 isoform of pyruvate kinase (PKM2).

Xu Y, Liu XH, Saunders M, Pearce S, Foulks JM, Parnell KM, Clifford A, Nix RN, Bullough J, Hendrickson TF, Wright K, McCullar MV, Kanner SB, Ho KK.

Bioorg Med Chem Lett. 2014 Jan 15;24(2):515-9. doi: 10.1016/j.bmcl.2013.12.028. Epub 2013 Dec 17.

PMID:
24374270
7.

SRChing for the substrates of Src.

Reynolds AB, Kanner SB, Bouton AH, Schaller MD, Weed SA, Flynn DC, Parsons JT.

Oncogene. 2014 Sep 11;33(37):4537-47. doi: 10.1038/onc.2013.416. Epub 2013 Oct 14. Review.

PMID:
24121272
8.

Synthesis and structure-activity relationship of 2-arylamino-4-aryl-pyrimidines as potent PAK1 inhibitors.

Xu Y, Foulks JM, Clifford A, Brenning B, Lai S, Luo B, Parnell KM, Merx S, McCullar MV, Kanner SB, Ho KK.

Bioorg Med Chem Lett. 2013 Jul 15;23(14):4072-5. doi: 10.1016/j.bmcl.2013.05.059. Epub 2013 May 28.

PMID:
23756368
9.

Pharmacologic activation of PKM2 slows lung tumor xenograft growth.

Parnell KM, Foulks JM, Nix RN, Clifford A, Bullough J, Luo B, Senina A, Vollmer D, Liu J, McCarthy V, Xu Y, Saunders M, Liu XH, Pearce S, Wright K, O'Reilly M, McCullar MV, Ho KK, Kanner SB.

Mol Cancer Ther. 2013 Aug;12(8):1453-60. doi: 10.1158/1535-7163.MCT-13-0026. Epub 2013 May 29.

10.

Discovery of 4-phenyl-2-phenylaminopyridine based TNIK inhibitors.

Ho KK, Parnell KM, Yuan Y, Xu Y, Kultgen SG, Hamblin S, Hendrickson TF, Luo B, Foulks JM, McCullar MV, Kanner SB.

Bioorg Med Chem Lett. 2013 Jan 15;23(2):569-73. doi: 10.1016/j.bmcl.2012.11.013. Epub 2012 Nov 16.

PMID:
23232060
11.

An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance.

Byers LA, Diao L, Wang J, Saintigny P, Girard L, Peyton M, Shen L, Fan Y, Giri U, Tumula PK, Nilsson MB, Gudikote J, Tran H, Cardnell RJ, Bearss DJ, Warner SL, Foulks JM, Kanner SB, Gandhi V, Krett N, Rosen ST, Kim ES, Herbst RS, Blumenschein GR, Lee JJ, Lippman SM, Ang KK, Mills GB, Hong WK, Weinstein JN, Wistuba II, Coombes KR, Minna JD, Heymach JV.

Clin Cancer Res. 2013 Jan 1;19(1):279-90. doi: 10.1158/1078-0432.CCR-12-1558. Epub 2012 Oct 22.

12.

Epigenetic drug discovery: targeting DNA methyltransferases.

Foulks JM, Parnell KM, Nix RN, Chau S, Swierczek K, Saunders M, Wright K, Hendrickson TF, Ho KK, McCullar MV, Kanner SB.

J Biomol Screen. 2012 Jan;17(1):2-17. doi: 10.1177/1087057111421212. Epub 2011 Sep 30. Review. Erratum in: J Biomol Screen. 2012 Jun;17(5):700.

PMID:
21965114
13.

Design, synthesis, and anti-inflammatory properties of orally active 4-(phenylamino)-pyrrolo[2,1-f][1,2,4]triazine p38alpha mitogen-activated protein kinase inhibitors.

Hynes J Jr, Dyckman AJ, Lin S, Wrobleski ST, Wu H, Gillooly KM, Kanner SB, Lonial H, Loo D, McIntyre KW, Pitt S, Shen DR, Shuster DJ, Yang X, Zhang R, Behnia K, Zhang H, Marathe PH, Doweyko AM, Tokarski JS, Sack JS, Pokross M, Kiefer SE, Newitt JA, Barrish JC, Dodd J, Schieven GL, Leftheris K.

J Med Chem. 2008 Jan 10;51(1):4-16. Epub 2007 Dec 12.

PMID:
18072718
14.

Monoclonal antibodies to six-transmembrane epithelial antigen of the prostate-1 inhibit intercellular communication in vitro and growth of human tumor xenografts in vivo.

Challita-Eid PM, Morrison K, Etessami S, An Z, Morrison KJ, Perez-Villar JJ, Raitano AB, Jia XC, Gudas JM, Kanner SB, Jakobovits A.

Cancer Res. 2007 Jun 15;67(12):5798-805.

15.

Discovery and SAR of 2-amino-5-(thioaryl)thiazoles as potent and selective Itk inhibitors.

Das J, Furch JA, Liu C, Moquin RV, Lin J, Spergel SH, McIntyre KW, Shuster DJ, O'Day KD, Penhallow B, Hung CY, Doweyko AM, Kamath A, Zhang H, Marathe P, Kanner SB, Lin TA, Dodd JH, Barrish JC, Wityak J.

Bioorg Med Chem Lett. 2006 Jul 15;16(14):3706-12. Epub 2006 May 6.

PMID:
16682193
16.

Discovery and SAR of 2-amino-5-[(thiomethyl)aryl]thiazoles as potent and selective Itk inhibitors.

Das J, Liu C, Moquin RV, Lin J, Furch JA, Spergel SH, Doweyko AM, McIntyre KW, Shuster DJ, O'Day KD, Penhallow B, Hung CY, Kanner SB, Lin TA, Dodd JH, Barrish JC, Wityak J.

Bioorg Med Chem Lett. 2006 May 1;16(9):2411-5. Epub 2006 Feb 14. Erratum in: Bioorg Med Chem Lett. 2006 Aug 1;16(15):4148. Doweyko, Arthur M [added].

PMID:
16481166
17.

Selective Itk inhibitors block T-cell activation and murine lung inflammation.

Lin TA, McIntyre KW, Das J, Liu C, O'Day KD, Penhallow B, Hung CY, Whitney GS, Shuster DJ, Yang X, Townsend R, Postelnek J, Spergel SH, Lin J, Moquin RV, Furch JA, Kamath AV, Zhang H, Marathe PH, Perez-Villar JJ, Doweyko A, Killar L, Dodd JH, Barrish JC, Wityak J, Kanner SB.

Biochemistry. 2004 Aug 31;43(34):11056-62.

PMID:
15323564
18.

Imidazoquinoxaline Src-family kinase p56Lck inhibitors: SAR, QSAR, and the discovery of (S)-N-(2-chloro-6-methylphenyl)-2-(3-methyl-1-piperazinyl)imidazo- [1,5-a]pyrido[3,2-e]pyrazin-6-amine (BMS-279700) as a potent and orally active inhibitor with excellent in vivo antiinflammatory activity.

Chen P, Doweyko AM, Norris D, Gu HH, Spergel SH, Das J, Moquin RV, Lin J, Wityak J, Iwanowicz EJ, McIntyre KW, Shuster DJ, Behnia K, Chong S, de Fex H, Pang S, Pitt S, Shen DR, Thrall S, Stanley P, Kocy OR, Witmer MR, Kanner SB, Schieven GL, Barrish JC.

J Med Chem. 2004 Aug 26;47(18):4517-29.

PMID:
15317463
19.

Discovery and initial SAR of 2-amino-5-carboxamidothiazoles as inhibitors of the Src-family kinase p56(Lck).

Wityak J, Das J, Moquin RV, Shen Z, Lin J, Chen P, Doweyko AM, Pitt S, Pang S, Shen DR, Fang Q, de Fex HF, Schieven GL, Kanner SB, Barrish JC.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):4007-10.

PMID:
14592495
20.

Altering T-cell activation by targeting the multidomain tyrosine kinase Itk.

Kanner SB, Perez-Villar JJ.

Trends Immunol. 2003 May;24(5):249-53. Review. No abstract available.

PMID:
12738418
21.

Phosphorylation of the linker for activation of T-cells by Itk promotes recruitment of Vav.

Perez-Villar JJ, Whitney GS, Sitnick MT, Dunn RJ, Venkatesan S, O'Day K, Schieven GL, Lin TA, Kanner SB.

Biochemistry. 2002 Aug 27;41(34):10732-40.

PMID:
12186560
22.

Nuclear localization of the tyrosine kinase Itk and interaction of its SH3 domain with karyopherin alpha (Rch1alpha).

Perez-Villar JJ, O'Day K, Hewgill DH, Nadler SG, Kanner SB.

Int Immunol. 2001 Oct;13(10):1265-74.

PMID:
11581171
23.

Focal adhesion kinase regulates beta1 integrin-dependent T cell migration through an HEF1 effector pathway.

van Seventer GA, Salmen HJ, Law SF, O'Neill GM, Mullen MM, Franz AM, Kanner SB, Golemis EA, van Seventer JM.

Eur J Immunol. 2001 May;31(5):1417-27.

24.
25.
26.

CD5 negatively regulates the T-cell antigen receptor signal transduction pathway: involvement of SH2-containing phosphotyrosine phosphatase SHP-1.

Perez-Villar JJ, Whitney GS, Bowen MA, Hewgill DH, Aruffo AA, Kanner SB.

Mol Cell Biol. 1999 Apr;19(4):2903-12.

27.

Integrin signalling defects in T-lymphocytes in systemic lupus erythematosus.

Ng TT, Collins IE, Kanner SB, Humphries MJ, Amft N, Wickremasinghe RG, D'Cruz D, Nye KE, Morrow WJ.

Lupus. 1999;8(1):39-51.

PMID:
10025598
28.

Mitogenic properties of a bispecific single-chain Fv-Ig fusion generated from CD2-specific mAb to distinct epitopes.

Connelly RJ, Hayden MS, Scholler JK, Tsu TT, Dupont B, Ledbetter JA, Kanner SB.

Int Immunol. 1998 Dec;10(12):1863-72.

PMID:
9885907
29.
30.

Interleukin-2 induces beta2-integrin-dependent signal transduction involving the focal adhesion kinase-related protein B (fakB).

Brockdorff J, Kanner SB, Nielsen M, Borregaard N, Geisler C, Svejgaard A, Odum N.

Proc Natl Acad Sci U S A. 1998 Jun 9;95(12):6959-64.

31.

Wiskott-Aldrich syndrome/X-linked thrombocytopenia: WASP gene mutations, protein expression, and phenotype.

Zhu Q, Watanabe C, Liu T, Hollenbaugh D, Blaese RM, Kanner SB, Aruffo A, Ochs HD.

Blood. 1997 Oct 1;90(7):2680-9.

PMID:
9326235
32.
33.

Dysfunctional focal adhesion kinase (pp125FAK) expression in HIV-infected donor T-cells.

Ng TT, Kanner SB, Humphries MJ, Wickremasinghe RG, Nye KE, Anderson J, Morrow WJ.

Biochem Soc Trans. 1997 May;25(2):219S. No abstract available.

PMID:
9191263
35.

The integrin-triggered rescue of T lymphocyte apoptosis is blocked in HIV-1-infected individuals.

Ng TT, Kanner SB, Humphries MJ, Wickremasinghe RG, Nye KE, Anderson J, Khoo SH, Morrow WJ.

J Immunol. 1997 Mar 15;158(6):2984-99.

PMID:
9058838
37.

A major tyrosine-phosphorylated protein of Trypanosoma brucei is a nucleolar RNA-binding protein.

Das A, Peterson GC, Kanner SB, Frevert U, Parsons M.

J Biol Chem. 1996 Jun 28;271(26):15675-81.

38.

ZAP-70 and p72syk are signaling response elements through MHC class II molecules.

Kanner SB, Grosmaire LS, Blake J, Schieven GL, Masewicz S, Odum N, Ledbetter JA.

Tissue Antigens. 1995 Sep;46(3 ( Pt 1)):145-54.

PMID:
8525473
40.

A role for CD5 in TCR-mediated signal transduction and thymocyte selection.

Tarakhovsky A, Kanner SB, Hombach J, Ledbetter JA, Müller W, Killeen N, Rajewsky K.

Science. 1995 Jul 28;269(5223):535-7.

PMID:
7542801
41.

Activation of murine T-cells via phospholipase-C gamma 1-associated protein tyrosine phosphorylation is reduced with aging.

Grossmann A, Rabinovitch PS, Kavanagh TJ, Jinneman JC, Gilliland LK, Ledbetter JA, Kanner SB.

J Gerontol A Biol Sci Med Sci. 1995 Jul;50(4):B205-12.

PMID:
7614232
42.

CD28 cross-linking augments TCR-mediated signals and costimulates superantigen responses.

Ohnishi H, Ledbetter JA, Kanner SB, Linsley PS, Tanaka T, Geller AM, Kotb M.

J Immunol. 1995 Apr 1;154(7):3180-93.

PMID:
7534790
43.
44.

Evidence for LFA-1/ICAM-1 dependent stimulation of protein tyrosine phosphorylation in human B lymphoid cell lines during homotypic adhesion.

Wang SC, Kanner SB, Ledbetter JA, Gupta S, Kumar G, Nel AE.

J Leukoc Biol. 1995 Feb;57(2):343-51.

PMID:
7852849
45.

Lymphocyte antigen receptor activation of a focal adhesion kinase-related tyrosine kinase substrate.

Kanner SB, Aruffo A, Chan PY.

Proc Natl Acad Sci U S A. 1994 Oct 25;91(22):10484-7.

46.

Coengagement of CD2 with LFA-1 or VLA-4 by bispecific ligand fusion proteins primes T cells to respond more effectively to T cell receptor-dependent signals.

Dietsch MT, Chan PY, Kanner SB, Gilliland LK, Ledbetter JA, Linsley PS, Aruffo A.

J Leukoc Biol. 1994 Oct;56(4):444-52.

PMID:
7523557
47.

ZAP-70 tyrosine kinase, CD45, and T cell receptor involvement in UV- and H2O2-induced T cell signal transduction.

Schieven GL, Mittler RS, Nadler SG, Kirihara JM, Bolen JB, Kanner SB, Ledbetter JA.

J Biol Chem. 1994 Aug 12;269(32):20718-26.

48.
49.

Developmental regulation of pp44/46, tyrosine-phosphorylated proteins associated with tyrosine/serine kinase activity in Trypanosoma brucei.

Parsons M, Ledbetter JA, Schieven GL, Nel AE, Kanner SB.

Mol Biochem Parasitol. 1994 Jan;63(1):69-78.

PMID:
8183324
50.

Human T and B lymphocytes express a structurally conserved focal adhesion kinase, pp125FAK.

Whitney GS, Chan PY, Blake J, Cosand WL, Neubauer MG, Aruffo A, Kanner SB.

DNA Cell Biol. 1993 Nov;12(9):823-30.

PMID:
7692878

Supplemental Content

Loading ...
Support Center